HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025

from Medical News Podcast · host PeerDirect Publishing

Drs. Dizon and Campos discuss how new antibody drug conjugates like trastuzumab deruxtecan are transforming treatment options for HER2+ gynecological cancers, showing promising results even in patients with low HER2 expression. They shared impressive clinical trial successes while emphasizing the importance of ongoing research into treatment sequencing and patient safety.

Episode metadata supplied by the publisher feed · Published Feb 18, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025

0:00 13:10

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical News Podcast?

This episode is 13 minutes long.

When was this Medical News Podcast episode published?

This episode was published on February 18, 2026.

Can I download this Medical News Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!